Background: Coronavirus disease 2019 (COVID-19) is a viral pneumonia infection that spreads rapidly globally (with a number of cases > 15,000,000 worldwide and mortality of ±4%) until it is designated a pandemic by the World Health Organization (WHO). One of the complications of COVID-19 is the incidence of coagulopathy and thromboembolism. The coronavirus, SARS-CoV-2, activates inflammatory and thrombotic processes. Coagulopathy and abnormal coagulation parameters are indicated among the most significant biomarkers of poor prognosis in COVID-19 patients. COVID-19-associated coagulopathy is characterized by a decreased platelet count and the presence of a cytokine storm indicating an extreme hypercoagulable state. This study aims to determine the coagulation profile of moderate-severe patients and outcomes in COVID-19 patients Methods: The study was conducted in a hospital in Makassar: Infection Center RS. Wahidin Sudirohusodo. Medical Record Data for all inpatients who have been diagnosed with COVID-19 through the RT-PCR test taken from January 2021-August 2021.Statistical tests in the form of the Kolmogorov-Smirnov test to assess the Normality of the Data, Chi-Square test, and the calculation of the out ratio (OR) Mann-Whitney test, Independent T-Test. Multivariate analysis was carried out using a Multiple Logistic Regression-Backward Wald Method. The results of the statistical test were significant if the p-value <0.05.   Results: The research subjects were 231 patients with confirmed COVID-19. The mean PT, D-Dimer, and Fibrinogen were higher in severe COVID-19 than moderate COVID-19 and had significant results. While PLT did not have significant results against moderate-severe COVID-19. The relationship between groups of coagulation marker variables was found to have a significant relationship with moderate to severe COVID-19. 4.     All coagulation markers were significantly related to the outcome (p<0.05). The mean value of each variable was found to be greater in patients with outcomes who died   Conclusion: There was an increase in all coagulation markers in moderate to severe COVID-19 except for PLT which was not significant. All coagulation markers are significantly related to outcome

Coronavirus is one of the pandemic diseases that infect millions of people worldwide. The aim of the study was a cross-sectional study of COVID-19 and its inflammatory markers in tertiary care hospitals in Peshawar, Pakistan. Samples of nasopharyngeal swabs were collected from 150 COVID-19 patients. Blood samples were collected aseptically in three different tubes to measure serum ferritin, D-dimer and CBC. The samples were further analysed at the PCR laboratory, Hayatabad Medical Complex, Peshawar. In the study, 100 samples were found positive based on PCR among 150 patients in which the D-dimer was reported to have a high relationship (95%) with inflammatory markers. Abnormal ferritin (87%), Hb (26%), neutrophil (73%) and abnormal lymphocytes were reported (63%) in patients. The relationship between the age factors with risk of inflammatory markers revealed that in the age group 61-80, ferritin, D-dimer, Hb, Neutrophil and lymphocytes were observed with abnormal levels 18, 20, 05, 14 and 13, respectively. The prevalence of COVID-19 infection was recorded as higher in males than females. The study showed that COVID-19 infection significantly affects the parameters, including abnormal ferritin levels in males 55% and females 32%. The male was reported with a high-level abnormal D-dimer (58%) than the female (37%). The other inflammatory markers, such as abnormal neutrophils and lymphocytes, counted 44 and 37% in males and females at 30 and 29%, respectively. The study concludes that an increase in inflammatory markers correlates with disease severity; this could be used as a significant prognostic factor of the disease. More advanced immunological studies need to explore the mechanism of COVID-19 with inflammatory markers.